A

PriceAutolus Therapeutics

AUTL

Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8.

Historical stock price chart and annual return over the past years

-63%

5 years

% Total

AUTL
-18%

5 years

Annual Return

AUTL